PE20040677A1 - Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) - Google Patents

Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap)

Info

Publication number
PE20040677A1
PE20040677A1 PE2003000697A PE2003000697A PE20040677A1 PE 20040677 A1 PE20040677 A1 PE 20040677A1 PE 2003000697 A PE2003000697 A PE 2003000697A PE 2003000697 A PE2003000697 A PE 2003000697A PE 20040677 A1 PE20040677 A1 PE 20040677A1
Authority
PE
Peru
Prior art keywords
agonists
polypeptide
vpac2
hypophyseal
pacap
Prior art date
Application number
PE2003000697A
Other languages
English (en)
Inventor
Wei Wang
Wayne A Froland
Michael L Dumas
James Whelan
Yu-Chang John Wang
Clark Pan
Drew N Kelner
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of PE20040677A1 publication Critical patent/PE20040677A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SE REFIERE A UN POLIPEPTIDO SELECCIONADO DEL GRUPO DE SEC ID NOs: 1 HASTA 152, DE PREFERENCIA SEC ID NOs: 1-5 Y SEC ID NOs: 115-119, SUS FRAGMENTOS, DERIVADOS Y VARIANTES FUNCIONALES EQUIVALENTES. UN METODO PARA PRODUCIR DICHO POLIPEPTIDO QUE COMPRENDE: A) CULTIVAR UNA CELULA HUESPED EN CONDICIONES APROPIADAS PARA LA EXPRESION DE DICHO POLIPEPTIDO; B) RECUPERAR EL POLIPEPTIDO DEL CULTIVO DE LACELULA HUESPED. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE PROPORCIONA ESTABILIDAD EN LA FORMULACION Y VIDA MEDIA PROLONGADA. DICHOS POLIPETIDOS SON AGONISTAS DEL RECEPTOR VPAC2, UTILES EN EL TRATAMIENTO DE DIABETES TIPO 2
PE2003000697A 2002-07-12 2003-07-11 Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) PE20040677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39573802P 2002-07-12 2002-07-12

Publications (1)

Publication Number Publication Date
PE20040677A1 true PE20040677A1 (es) 2004-10-29

Family

ID=30115918

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000697A PE20040677A1 (es) 2002-07-12 2003-07-11 Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap)

Country Status (20)

Country Link
US (2) US7378494B2 (es)
EP (1) EP1578358A2 (es)
JP (1) JP2006506969A (es)
CN (1) CN101405298A (es)
AR (1) AR040548A1 (es)
AU (1) AU2003267990A1 (es)
BR (1) BR0312621A (es)
CA (1) CA2491279A1 (es)
DO (1) DOP2003000669A (es)
GT (1) GT200300142A (es)
HN (1) HN2003000217A (es)
IL (1) IL165499A (es)
MX (1) MXPA04012305A (es)
PE (1) PE20040677A1 (es)
PL (1) PL377025A1 (es)
RU (1) RU2360922C2 (es)
TW (1) TW200409641A (es)
UY (1) UY27893A1 (es)
WO (1) WO2004006839A2 (es)
ZA (1) ZA200501118B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301431D0 (sv) * 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
EP1713493A4 (en) * 2004-01-27 2009-06-24 Bayer Pharmaceuticals Corp PEPTIDE-RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND PHARMACOLOGICAL METHODS OF USING THESE AGONISTS
DE602005005476T2 (de) * 2004-05-21 2009-03-05 Eli Lilly And Co., Indianapolis Selektive peptidische agonisten des vpac2-rezeptors
ATE412010T1 (de) * 2004-05-21 2008-11-15 Lilly Co Eli Selektive peptidische agonisten des vpac2- rezeptors
CA2858901C (en) 2004-06-04 2024-01-16 Carolyn Anderson Diabetes care host-client architecture and data management system
CN101001639A (zh) * 2004-06-12 2007-07-18 拜尔药品公司 血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法
US20080318845A1 (en) * 2004-08-18 2008-12-25 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
US20090170775A1 (en) * 2004-10-08 2009-07-02 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide compositions
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20080214440A1 (en) * 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US20070293429A1 (en) * 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
KR20070067136A (ko) 2004-10-08 2007-06-27 포베스 메디-테크 (리서치) 인코포레이티드 혈관작용성 장내 폴리펩티드 제약
WO2006053646A2 (en) * 2004-11-19 2006-05-26 Novosom Ag Improvements in or relating to pharmaceutical compositions for local administration
WO2006068813A1 (en) * 2004-12-21 2006-06-29 Noveon, Inc. Compositions
ATE509634T1 (de) * 2005-04-08 2011-06-15 Amylin Pharmaceuticals Inc Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
EP1896048A4 (en) * 2005-05-06 2010-11-03 Bayer Pharmaceuticals Corp PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE
CA2618740A1 (en) * 2005-08-11 2007-02-22 Eli Lilly And Company Selective vpac2 receptor peptide agonists
CN101296708B (zh) 2005-10-26 2011-12-07 伊莱利利公司 选择性vpac2受体肽激动剂
CA2638733A1 (en) * 2006-02-28 2007-09-07 Eli Lilly And Company Selective vpac2 receptor peptide agonists
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
US8980254B2 (en) 2008-08-21 2015-03-17 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
CN106794217A (zh) * 2014-08-06 2017-05-31 血管生物科学 包含对患病组织具有选择性的药效团的组合物及其制备方法
WO2016168768A2 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
US10202435B2 (en) 2016-04-15 2019-02-12 Alder Biopharmaceuticals, Inc. Anti-PACAP antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) * 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use

Also Published As

Publication number Publication date
HN2003000217A (es) 2004-07-26
UY27893A1 (es) 2003-12-31
US20040058870A1 (en) 2004-03-25
PL377025A1 (pl) 2006-01-23
GT200300142A (es) 2004-03-17
US7378494B2 (en) 2008-05-27
RU2005103396A (ru) 2005-09-20
WO2004006839A2 (en) 2004-01-22
AR040548A1 (es) 2005-04-13
CA2491279A1 (en) 2004-01-22
ZA200501118B (en) 2006-08-30
AU2003267990A1 (en) 2004-02-02
CN101405298A (zh) 2009-04-08
EP1578358A2 (en) 2005-09-28
TW200409641A (en) 2004-06-16
US20090258826A1 (en) 2009-10-15
DOP2003000669A (es) 2004-01-31
BR0312621A (pt) 2005-12-06
IL165499A (en) 2010-12-30
JP2006506969A (ja) 2006-03-02
IL165499A0 (en) 2006-01-15
MXPA04012305A (es) 2005-02-25
RU2360922C2 (ru) 2009-07-10

Similar Documents

Publication Publication Date Title
PE20040677A1 (es) Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap)
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
Colmers et al. Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor.
ES2351661T3 (es) Péptido-2 análogo al glucagón.
PE20090932A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
AR050353A1 (es) Composicion de anticuerpo her2
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
PH12014501642A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
PE20090682A1 (es) Secuencias peptidicas y composiciones
ES2137182T3 (es) Derivados recombinantes del factor viii humano.
Gray et al. Characterization, primary structure, and evolution of lamprey plasma albumin
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
TR201903610T4 (tr) Alfa-melanosit uyarici hormonlarin peptid analoglari.
NO20053761L (no) Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus.
AR040226A1 (es) Productos parenterales antifungicos
MX2012014573A (es) Agentes medicinales unidos a dipeptido.
KR960704041A (ko) 사람 인터루킨-10의 효능제 및 길항제(Agonists and antagonists of human interleukin-10)
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
CA2988841C (en) Protease-resistant lipidated glp-1 analogs
HU227908B1 (en) Disulfide cross-linked glycoprotein hormones, their preparation and use thereof
PE20211457A1 (es) Conjugados del peptido de fusion peptido similar al glucagon 1 (glp-1) acoplado al peptido tirosina tirosina ciclico y usos de estos
JP2010083896A (ja) ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed